已审批感染治疗新进展.pptx

G+感染治疗新进展仅供医疗专业人士参考审批编号：281003.022有效期：2015/11/20

G+菌(N=20354)汪复等.中国感染与化疗杂志2013;13:321-330.中国2012年CHINET耐药监测

FreifeldAGetal.ClinInfectDis2011;52:427-31.HuangXJ,etal.IntJAntimicrobAgents2005;26:S128-32.IDST.JMicrobiolImmunolInfect2005;38:455-7.Asia

葡萄球菌中耐甲氧西林的菌株检出率(%)汪复等.中国感染与化疗杂志2013;13:321-330.中国2012年CHINET耐药监测

金黄色葡萄球菌对抗菌药物的敏感率敏感率(%)舒巴坦汪复等.中国感染与化疗杂志2013;13:321-330.中国2012年CHINET耐药监测

PrevalenceRatesofhVISAandVISA

amongMRSAIsolatesinAsia%ofisolateshVISAVISA(2005-6,n=56)(2005-7,n=1043)(2006-7,n=361)(2003,n=100)EJCMID2009AAC2009JCM2009IJAA200512.5(2009-2010,n=63)InfectGenetEvol2013Japan:hVISA(5.1%/750MRSA)waspresentinhospitalsbeforeclinicalintroductionofycin(1990)JInfectChemother2012;18:406-9.Korea:hVISAphenotypeinone-thirdMRSA(ycinMIC?2?g/ml)JAntimicrobChemother2012;67:1843-9.JInfectChemother2012;18:406-9;JAntimicrobChemother2012;67:1843-9.

MICsof393MRSAIsolatesByAgarDilutionandOtherMethodsChenSY,HsuehPRetal.JAntimicrobChemother2014;69:211-8.

肠球菌对抗菌药物的敏感率敏感率(%)汪复等.中国感染与化疗杂志2013;13:321-330.中国2012年CHINET耐药监测

AntimicrobialStewardship

DellitTetal.ClinInfectDis2007;44:159-177.ThePrimaryGoalofAntimicrobialStewardship:“Optimizeclinicaleswhileminimizingunintendedconsequencesofantimicrobialuse”抗生素管理

ialMRSABacteremia

MortalitybasedonycinMICsWangJLetal.BMCInfectDis2010RiskfactorsofhighMIC:PatientsintheICU,ycinexposure,prolongedhospitalizationLodiseTPetal2008JAC.Wangetal,2010BMCID

HolmesNEetal.JInfectDis2011;204:340AntibioticChoiceMayNotExplainPooreresinPatientswithS.aureusBacteremiaandHighycinMICsP0.001

PatelNetal.ClinInfectDis2011;52:969-74.ycinProbabilityofAchievinganAUC/MICRatioMICValue,andProbabilityofaNephrotoxicEvent

MIC(?g/ml)%ofIsolates?0.25?8MICDistributionofMRSA(N=1725)ycin,TIST,2006-2010ChenYH,HsuehPR,etal.